Business

Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New Business

Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New Business

articleHob Biotech Group Corp., Ltd. Class ASeptember 24, 20253/news/announcement-on-progress-in-voluntary-disclosure-of-phase-iii-clinical-trial-of-mm09-sublingual-spray-for-allergy-immunotherapy-completes-enrollment-of-first-subjects-along-with-new-business
Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New Business

About this update from Hob Biotech Group Corp., Ltd. Class A

Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New BusinessThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hob Biotech Group Corp., Ltd. Class A